Producer
SHL Medical
Major merchant manufacturer of disposable autoinjectors (Molly platform) for GLP-1 and other self-administered biologics.
1
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
1 input SHL Medical supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something SHL Medical makes — pick one to see the full supply chain.
Where they make it
2 facilities
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Advanced Drug Delivery Systems (autoinjectors)
Pen injectors & other self-injection devices
Vertically integrated manufacturing (in-house)
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2024
Taiwan is famous as the semiconductor chokepoint. It is also, far less visibly, a chokepoint for injectable-drug delivery devices: SHL Medical — the largest independent autoinjector manufacturer in the world, whose Molly platform delivers GLP-1 obesity drugs and a broad range of self-administered biologics — concentrates its core production in Taiwan (Taoyuan and Zhubei). A Taiwan Strait disruption that the market models as a "chips" event would simultaneously threaten the physical means of delivering Ozempic/Wegovy-class drugs and autoimmune, migraine and osteoporosis biologics to patients worldwide. The same geography underwrites two completely different essential-supply chains, and almost no risk model connects them.
SHL Medical AG ↗Did you know2024
In 2024 reporting SHL Medical reads as "the GLP-1 autoinjector company," but the Molly platform is the delivery device beneath a much wider set of drug classes: autoimmune biologics (adalimumab and biosimilars for rheumatoid arthritis and psoriasis), migraine CGRP antibodies, osteoporosis injections, and other self-administered antibodies. Because these all draw on the same finite Molly device lines and assembly capacity, the surge of GLP-1 demand directly competes for the autoinjectors that rheumatoid-arthritis, psoriasis and migraine patients depend on. The obesity-drug boom is quietly rationing device capacity across unrelated chronic-disease categories — a cross-industry squeeze hidden inside a single contract device maker.
SHL Medical AG ↗Origin2024
SHL Medical began as "Scandinavian Health Limited," founded in 1989 by Swedish entrepreneur Roger Samuelsson, but it built the bulk of its manufacturing in Taiwan rather than Europe. Over three decades the group grew from a contract maker into the world's largest independent (merchant) manufacturer of disposable autoinjectors, on the strength of deep in-house vertical integration — it molds its own micro-components and even designs and builds its own assembly automation. The corporate headquarters later moved to Zug, Switzerland, but the production center of gravity stayed in Taiwan. So the device that delivers a large share of the West's self-injected biologics is made by a Swedish-founded, Swiss-headquartered company whose factories sit on the same island as the world's leading-edge chip fabs.
SHL Medical AG ↗Capacity2024
To diversify away from a Taiwan-only manufacturing base and meet GLP-1-driven demand, SHL Medical has been building out major new capacity in the United States — a large device-manufacturing campus in the North Charleston, South Carolina area — alongside continued Taiwan and European (Switzerland, Germany) operations. The build-out is a direct response to both the scale of autoinjector demand and customer pressure to reduce single-geography concentration risk. The scale of the new-site investment is itself evidence that the binding GLP-1 constraint is device assembly capacity, not drug substance. [verify: North Charleston SC campus, GLP-1-driven, Taiwan-diversify confirmed]
SHL Medical AG ↗